Abstract
Somatostatin (SST) analogues play an important role in the medical management of somatotroph pituitary adenomas and new agonists have the potential to be effective in a wider group of pituitary and other tumours. The anti-proliferative effect of SST occurs through multiple mechanisms, one of which is cell-cycle arrest, where p27, a cyclin-dependent kinase inhibitor, is an important regulator. We hypothesised that SST may upregulate p27 protein levels and downregulate the MAP kinase pathway in these tumours.
Publication information
Hubina E, Nanzer AM, Hanson MR, et al 'Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours' European Journal of Endocrinology 2006 Aug;155(2):371-9